Novartis (NVS -0.1%) will stop testing on its experimental lung-cancer drug after studies showed...

|About: Novartis AG (NVS)|By:, SA News Editor

Novartis (NVS -0.1%) will stop testing on its experimental lung-cancer drug after studies showed it had little or no impact on survival rates, and will take a $120M charge against Q4 earnings as a result. Novartis is eager to find replacement revenue for expiring patents, but is having only mixed success.